EGFR and non-small cell lung carcinoma: The combination of bevacizumab with ICIs and platinum‐containing chemotherapy (ABCP) has shown substantial survival benefits in patients with metastatic NSCLC with active EGFR mutations who are resistant to EGFR‐TKIs (a population that was previously considered unfriendly to immunotherapy) compared with BCP treatment [15], verifying their synergistic effect.